Reduction in surgical site infections by localized administration with D-PLEX100 in patients with multiple risk factors undergoing colorectal surgery

Anthony J. Senagore; Yafit Stark; Olga Belotserkovsky; Malka Reichert; Nir Wasserberg; Hagit Tulchinsky; Lior Segev; Oded Zmora; Goldi A. Kozloski; Noam Emanuel

doi:10.1016/j.amjsurg.2022.11.021

Reduction in surgical site infections by localized administration with D-PLEX₁₀₀ in patients with multiple risk factors undergoing colorectal surgery

Anthony J. Senagore^*, Yafit Stark, Olga Belotserkovsky, Malka Reichert, Nir Wasserberg, Hagit Tulchinsky, Lior Segev, Oded Zmora, Goldi A. Kozloski, Noam Emanuel

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background: D-PLEX₁₀₀ is a novel drug-eluting lipid polymer matrix that supplies a high, local concentration of doxycycline for approximately 30 days. The objective of this post-hoc analysis was to assess the efficacy of D-PLEX₁₀₀ in preventing superficial and deep SSIs in patients with ≥2 risk factors. Patients and methods: A post-hoc analysis of a previously reported prospective randomized trial assessing D-PLEX₁₀₀ plus Standard of Care (SOC) versus SOC alone in colorectal surgery was performed to assess SSI rate in patients with ≥2 risk factors. Results: The overall incidence of SSI was significantly lower for the D-PLEX₁₀₀ arm (9.9%) versus SOC (21%), p = 0.033. Patients with ≥2 risk factors, SSI incidence was 37.5% for SOC and 15.8% in D-PLEX₁₀₀ treated patients. Conclusions: D-PLEX₁₀₀ reduces the incidence of SSIs beyond benefits associated with SOC treatment alone and including patients with ≥2 risk factors. D-PLEX₁₀₀ may be a promising addition to established SSI prophylaxis bundles.

Original language	English
Pages (from-to)	485-488
Number of pages	4
Journal	American Journal of Surgery
Volume	225
Issue number	3
DOIs	https://doi.org/10.1016/j.amjsurg.2022.11.021
State	Published - Mar 2023
Externally published	Yes

Funding

Funders	Funder number
PolyPid
PolyPid, Ltd.

Keywords

Doxycycline
Localized antibiotic therapy
Risk factors
Surgical site infection

Access to Document

10.1016/j.amjsurg.2022.11.021

Cite this

Senagore, A. J., Stark, Y., Belotserkovsky, O., Reichert, M., Wasserberg, N., Tulchinsky, H., Segev, L., Zmora, O., Kozloski, G. A., & Emanuel, N. (2023). Reduction in surgical site infections by localized administration with D-PLEX₁₀₀ in patients with multiple risk factors undergoing colorectal surgery. American Journal of Surgery, 225(3), 485-488. https://doi.org/10.1016/j.amjsurg.2022.11.021

@article{bfab0b03b85245629ffe70db778c247e,

title = "Reduction in surgical site infections by localized administration with D-PLEX100 in patients with multiple risk factors undergoing colorectal surgery",

abstract = "Background: D-PLEX100 is a novel drug-eluting lipid polymer matrix that supplies a high, local concentration of doxycycline for approximately 30 days. The objective of this post-hoc analysis was to assess the efficacy of D-PLEX100 in preventing superficial and deep SSIs in patients with ≥2 risk factors. Patients and methods: A post-hoc analysis of a previously reported prospective randomized trial assessing D-PLEX100 plus Standard of Care (SOC) versus SOC alone in colorectal surgery was performed to assess SSI rate in patients with ≥2 risk factors. Results: The overall incidence of SSI was significantly lower for the D-PLEX100 arm (9.9%) versus SOC (21%), p = 0.033. Patients with ≥2 risk factors, SSI incidence was 37.5% for SOC and 15.8% in D-PLEX100 treated patients. Conclusions: D-PLEX100 reduces the incidence of SSIs beyond benefits associated with SOC treatment alone and including patients with ≥2 risk factors. D-PLEX100 may be a promising addition to established SSI prophylaxis bundles.",

keywords = "Doxycycline, Localized antibiotic therapy, Risk factors, Surgical site infection",

author = "Senagore, {Anthony J.} and Yafit Stark and Olga Belotserkovsky and Malka Reichert and Nir Wasserberg and Hagit Tulchinsky and Lior Segev and Oded Zmora and Kozloski, {Goldi A.} and Noam Emanuel",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2023",

month = mar,

doi = "10.1016/j.amjsurg.2022.11.021",

language = "אנגלית",

volume = "225",

pages = "485--488",

journal = "American Journal of Surgery",

issn = "0002-9610",

publisher = "Elsevier Inc.",

number = "3",

}

Senagore, AJ, Stark, Y, Belotserkovsky, O, Reichert, M, Wasserberg, N , Tulchinsky, H , Segev, L , Zmora, O, Kozloski, GA & Emanuel, N 2023, 'Reduction in surgical site infections by localized administration with D-PLEX₁₀₀ in patients with multiple risk factors undergoing colorectal surgery', American Journal of Surgery, vol. 225, no. 3, pp. 485-488. https://doi.org/10.1016/j.amjsurg.2022.11.021

TY - JOUR

T1 - Reduction in surgical site infections by localized administration with D-PLEX100 in patients with multiple risk factors undergoing colorectal surgery

AU - Senagore, Anthony J.

AU - Stark, Yafit

AU - Belotserkovsky, Olga

AU - Reichert, Malka

AU - Wasserberg, Nir

AU - Tulchinsky, Hagit

AU - Segev, Lior

AU - Zmora, Oded

AU - Kozloski, Goldi A.

AU - Emanuel, Noam

PY - 2023/3

Y1 - 2023/3

N2 - Background: D-PLEX100 is a novel drug-eluting lipid polymer matrix that supplies a high, local concentration of doxycycline for approximately 30 days. The objective of this post-hoc analysis was to assess the efficacy of D-PLEX100 in preventing superficial and deep SSIs in patients with ≥2 risk factors. Patients and methods: A post-hoc analysis of a previously reported prospective randomized trial assessing D-PLEX100 plus Standard of Care (SOC) versus SOC alone in colorectal surgery was performed to assess SSI rate in patients with ≥2 risk factors. Results: The overall incidence of SSI was significantly lower for the D-PLEX100 arm (9.9%) versus SOC (21%), p = 0.033. Patients with ≥2 risk factors, SSI incidence was 37.5% for SOC and 15.8% in D-PLEX100 treated patients. Conclusions: D-PLEX100 reduces the incidence of SSIs beyond benefits associated with SOC treatment alone and including patients with ≥2 risk factors. D-PLEX100 may be a promising addition to established SSI prophylaxis bundles.

AB - Background: D-PLEX100 is a novel drug-eluting lipid polymer matrix that supplies a high, local concentration of doxycycline for approximately 30 days. The objective of this post-hoc analysis was to assess the efficacy of D-PLEX100 in preventing superficial and deep SSIs in patients with ≥2 risk factors. Patients and methods: A post-hoc analysis of a previously reported prospective randomized trial assessing D-PLEX100 plus Standard of Care (SOC) versus SOC alone in colorectal surgery was performed to assess SSI rate in patients with ≥2 risk factors. Results: The overall incidence of SSI was significantly lower for the D-PLEX100 arm (9.9%) versus SOC (21%), p = 0.033. Patients with ≥2 risk factors, SSI incidence was 37.5% for SOC and 15.8% in D-PLEX100 treated patients. Conclusions: D-PLEX100 reduces the incidence of SSIs beyond benefits associated with SOC treatment alone and including patients with ≥2 risk factors. D-PLEX100 may be a promising addition to established SSI prophylaxis bundles.

KW - Doxycycline

KW - Localized antibiotic therapy

KW - Risk factors

KW - Surgical site infection

UR - http://www.scopus.com/inward/record.url?scp=85144925246&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2022.11.021

DO - 10.1016/j.amjsurg.2022.11.021

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 36567225

AN - SCOPUS:85144925246

SN - 0002-9610

VL - 225

SP - 485

EP - 488

JO - American Journal of Surgery

JF - American Journal of Surgery

IS - 3

ER -